CN Patent

CN115484940A — 用于鼻内递送的肾上腺素药物制剂

Assigned to Amphastar Pharmaceuticals Inc · Expires 2022-12-16 · 3y expired

What this patent protects

本公开介绍了用于鼻内(IN)递送的药物制剂，该药物制剂具有作为活性药物成分(API)的肾上腺素和作为吸收增强剂的胆汁酸或其盐(例如，牛磺胆酸钠(STC))。胆汁酸或其盐通过IN递送增强肾上腺素的吸收。还公开了使用所公开的用于各种治疗或适应症的肾上腺素制剂通过IN递送向患者施用肾上腺素的方法。

USPTO Abstract

本公开介绍了用于鼻内(IN)递送的药物制剂，该药物制剂具有作为活性药物成分(API)的肾上腺素和作为吸收增强剂的胆汁酸或其盐(例如，牛磺胆酸钠(STC))。胆汁酸或其盐通过IN递送增强肾上腺素的吸收。还公开了使用所公开的用于各种治疗或适应症的肾上腺素制剂通过IN递送向患者施用肾上腺素的方法。

Drugs covered by this patent

Epipen (epinephrine) · Pfizer Inc.

Patent Metadata

Patent number: CN115484940A
Jurisdiction: CN
Classification: —
Expires: 2022-12-16
Drug substance claim: No
Drug product claim: No
Assignee: Amphastar Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.